SystImmune, Inc. Appoints Dr. Jie D'Elia as Chief Executive Officer
Dr. D'Elia's extensive experience in drug development, strategic planning, and business development is poised to propel SystImmune into its next phase of growth and innovation.
- Dr. D'Elia's extensive experience in drug development, strategic planning, and business development is poised to propel SystImmune into its next phase of growth and innovation.
- I look forward to working with her as we steer SystImmune towards new horizons of development and success."
- Its highly differentiated platforms discovering bi-specific and multi-specific antibodies and ADCs stand out as a testament to its innovative capabilities.
- Dr. D'Elia received her Ph.D. from the College of Pharmacy at the University of Texas at Austin and her MBA from Columbia Business School.